Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

meeting

Update: FDA acknowledges late mortality signal with paclitaxel devices

The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

August 7, 2019
heart.jpg

‘Heart-on-a-chip’ system replicates human drug response

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

August 7, 2019
Patients who take diuretics, renin-angiotensin system (RAD) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) at the same time face a much higher risk of developing acute kidney injury (AKI)

NSAIDs heighten CV risk in patients with osteoarthritis

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.

August 7, 2019

JUUL Labs: A case study in ethical vaping research

An editorial published in The Lancet August 2 scrutinized JUUL Labs’ participation in and sponsorship of e-cigarette research in the U.S., finding the vaping giant fell short in seven of eight categories designed to test ethical integrity.

August 2, 2019
syringe-3902915_960_720.jpg

Hep C hikes risk of CVD by 28%

Individuals infected with hepatitis C are at a significantly increased risk of developing heart disease, according to a Lancet analysis that also found hep C-linked CVD is responsible for 1.5 million disability-adjusted life-years (DALYs) annually.

August 1, 2019
hemp-leaf-3661209_960_720.jpg

Soy compound could protect heart from cannabis-related damage

An antioxidant compound found in soybeans might protect the heart from cannabis-related CV damage, according to work presented at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions.

July 31, 2019

‘Electrocardiomatrix’ beats standard methods of detecting AFib in stroke units

Researchers at the University of Michigan have developed technology that flags stroke victims at the greatest risk for atrial fibrillation after an event, trumping standard methods of risk stratification to achieve greater accuracy.

July 18, 2019
ecigarette-3576177_960_720.jpg

Judge sets 10-month deadline for e-cig makers to apply for federal approval

A federal judge has set a 10-month deadline, ending in May 2020, for e-cigarette and cigar makers to apply for FDA authorization to keep their products on the market.

July 16, 2019

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup